NewsRamp is a PR & Newswire Technology platform that enhances press release distribution by adapting content to align with how and where audiences consume information. Recognizing that most internet activity occurs outside of search, NewsRamp improves content discovery by programmatically curating press releases into multiple unique formats—news articles, blog posts, persona-based TLDRs, videos, audio, and Zero-Click content—and distributing this content through a network of news sites, blogs, forums, podcasts, video platforms, newsletters, and social media.
FAQ: TransCode Therapeutics and Quantum Leap Collaboration on TTX-MC138 Clinical Trial
TL;DR
TransCode Therapeutics gains a strategic advantage by testing TTX-MC138 in the PRE-I-SPY trial, potentially positioning its RNA therapy as a leading precision treatment for colorectal cancer recurrence.
TransCode's TTX-MC138 will be evaluated in a Phase 2a trial starting in 2026, targeting ctDNA-positive colorectal cancer patients to assess biological activity in minimal residual disease.
This collaboration aims to develop better treatments for colorectal cancer patients at high risk of recurrence, potentially improving survival and quality of life through precision medicine.
TransCode is pioneering an RNA therapy targeting a specific metastasis biomarker, exploring a novel approach to treat cancer that has spread at the microscopic level.
Found this article helpful?
Share it with your network and spread the knowledge!
TransCode Therapeutics and Quantum Leap Healthcare Collaborative announced a collaboration to evaluate TransCode's lead therapeutic candidate TTX-MC138 in the PRE-I-SPY Phase 2a clinical trial platform for colorectal cancer patients.
TTX-MC138 is TransCode Therapeutics' lead therapeutic candidate focused on treating metastatic tumors that overexpress microRNA-10b, a unique, well-documented biomarker of metastasis.
The trial plans to enroll up to 45 colorectal cancer patients who are ctDNA positive following standard curative-intent therapy, specifically those in the minimal residual disease setting where recurrence risk is high.
The study is scheduled to begin in the first half of 2026.
The study will be led by Dr. Paula Pohlmann of MD Anderson Cancer Center.
This collaboration reflects growing interest in precision treatments targeting micrometastatic disease, addressing a critical need in cancer treatment where recurrence risk is high and therapeutic options are limited.
TransCode Therapeutics is a clinical stage company pioneering immunoncology and RNA therapeutic treatments of high risk and advanced cancers, with a portfolio of first-in-class therapeutic candidates designed to mobilize the immune system to recognize and destroy cancer cells.
The latest news and updates relating to RNAZ are available in the company's newsroom at https://ibn.fm/RNAZ.
The PRE-I-SPY is a Phase 2a clinical trial platform that will assess the biological and clinical activity of TTX-MC138 in the minimal residual disease setting for colorectal cancer patients.
The full press release can be viewed at https://ibn.fm/iX3ak.
Curated from InvestorBrandNetwork (IBN)
